German biopharmaceutical sales increased 11% to €6 billion ($8.3 billion) in 2012, according to the Boston Consulting Group’s “Biotech Report 2013” released in June. Biopharmaceutical sales comprised 21% of the German pharmaceutical market last year, up from 19% in 2011. The growth in biopharmaceutical revenues was led by an increase in prescriptions for severe diseases. There were 28 new drugs approved in Germany in 2012, 18% of which were biopharmaceuticals. The number of biopharmaceuticals in the clinical development phase increased 4% to 578. Of the 385 German firms that were involved in biotechnology in 2012, 30% developed biopharmaceuticals, and 70% did not produce their own pharmaceuticals but utilized their own technology platforms for drug development. The number of employees in medical biotech grew less than 1% to 36,000.

Source: Boston Consulting Group